News · 26 weeks40+100%
2025-10-262026-04-19
Mix2990d
- Other10(34%)
- SEC Filings9(31%)
- Insider4(14%)
- Offering3(10%)
- Earnings2(7%)
- Dividends1(3%)
Latest news
25 items- SECSEC Form DEFA14A filed by Seer Inc.DEFA14A - Seer, Inc. (0001726445) (Filer)
- SECSEC Form DEFA14A filed by Seer Inc.DEFA14A - Seer, Inc. (0001726445) (Filer)
- SECSeer Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Seer, Inc. (0001726445) (Filer)
- SECSEC Form DFAN14A filed by Seer Inc.DFAN14A - Seer, Inc. (0001726445) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Seer Inc.SCHEDULE 13D/A - Seer, Inc. (0001726445) (Subject)
- PRSeer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC GroupREDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed that it has received a highly contingent, non-binding and unsolicited proposal from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group") to acquire all of the outstanding shares of Seer's Class A common stock for $2.25 per share in cash plus a contingent value right (the "Proposal"). Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Seer Board of Directors (the "Board") will carefully
- PRThe Radoff-JEC Group Submits Non-Binding Proposal to Acquire Seer, Inc.Proposal Provides Stockholders $2.25 per Share in Cash, a 33% Premium to the Most Recent Closing Price, as Well as Potential Additional Value from the Sale of Seer's Assets via a Contingent Value Right Proposal Provides Seer Stockholders Immediate and Significant Value While Avoiding Further Value Destruction from Continued Abysmal Operating Results Nominates Three Highly Qualified Director Candidates – Howard H. Berman, Joshua S. Horowitz and Luis E. Rinaldini – for Election at Upcoming Annual Meeting Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group"), who collectively own approximately 7.6% of the outstanding shares of Seer, Inc.
- PRSeer and Precision Health Research, Singapore Sign Collaboration to Provide Deep, Unbiased Proteomics on 10,000 PRECISE SG100K SamplesREDWOOD CITY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Proteograph® Product Suite, has been selected as the mass spectrometry-based proteomic workflow to deeply profile the plasma proteome in 10,000 participants from PRECISE-SG100K. This unbiased proteomics data set will be combined with data from Thermo Fisher Scientific's Olink® Reveal and Thermo Scientific Orbitrap Astral™ mass spectrometers, utilized on the same set of samples to enhance the proteomic insights available to researchers. PRECISE-SG100K is a landmark, multi-ancestry population-scale cohort of approx
- SECSeer Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Seer, Inc. (0001726445) (Filer)
- PRPatent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker SubsidiariesREDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leader in deep, unbiased proteomic insights, today announced that the Patent Trial and Appeal Board ("PTAB") of the U.S. Patent and Trademark Office issued a Final Written Decision on March 23, 2026, in an inter partes review of U.S. Patent No. 11,435,360 B2 (the "'360 Patent"). The inter partes review was filed by PreOmics GmbH and Biognosys AG, each a subsidiary of Bruker Corporation, challenging 11 of 29 claims of the '360 Patent. The '360 Patent covers methods for analyzing biological samples using engineered nano- and microparticles that form protein coronas, resulting in protein enrichment that unde
- SECAmendment: SEC Form 8-A12B/A filed by Seer Inc.8-A12B/A - Seer, Inc. (0001726445) (Filer)
- SECSeer Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits8-K - Seer, Inc. (0001726445) (Filer)
- PRThe Radoff-JEC Group Sends Open Letter to Seer, Inc. Unconflicted Independent Directors Meeta Gulyani and Nicolas RoelofsRaises Concerns About the Board's Continued Deference to Chair and CEO Dr. Omid Farokhzad in Light of His Track Record of Value Destruction Highlights Recently Filed Stockholder Lawsuit Against Seer and its Board Members, Which Alleges the Board Breached its Fiduciary Duties in Connection with the Adoption of the NOL Poison Pill Calls on the Board to Immediately Announce a Sale Process to Avoid Further Value Destruction Under Dr. Farokhzad Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group"), who collectively own approximately 7.6% of the outstanding common stock of Seer, Inc. (NASDAQ:SEER), today issued the following open letter to i
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Seer Inc.SCHEDULE 13D/A - Seer, Inc. (0001726445) (Subject)
- SECSEC Form 10-K filed by Seer Inc.10-K - Seer, Inc. (0001726445) (Filer)
- SECSEC Form 8-A12B filed by Seer Inc.8-A12B - Seer, Inc. (0001726445) (Filer)
- SECSeer Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Seer, Inc. (0001726445) (Filer)
- SECSeer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Seer, Inc. (0001726445) (Filer)
- PRSeer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax AssetsREDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a tax benefit preservation plan ("NOL Plan") designed to help preserve and protect Seer's valuable income tax net operating loss carryforwards and other tax assets ("NOLs"). As of December 31, 2025, Seer had approximately $262 million of NOLs. These NOLs, most of which are not currently subject to any expiration date, represent a valuable asset of Seer and are available to reduce Seer's future federal income tax expense. The NOL Plan is similar to those adopted by numerous o
- PRSeer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 OutlookREDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Generated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during the full year 2025Seminal customer studies published in Nature and Nature Genetics highlighting the power of the Proteograph to enable clinically relevant biomarker discovery and deep biologic insigh
- PRThe Radoff-JEC Group Issues Open Letter to Seer Inc.'s Board of Directors Regarding the Immediate Need for Significant ChangeHighlights Seer's Abysmal Operating Results and Severe Undervaluation Under the Leadership of Co-Founder, Board Chair and CEO Dr. Omid Farokhzad Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group"), who collectively own nearly 7.5% of the outstanding common stock of Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), today issued the following open letter to the Company's Board of Directors. *** February 23, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 Attn: The Board of Directors Members of the Board of Directors (the "Board"), We are stockholders of Seer, Inc. ("Seer" or the "Company"), with ow
- SECSEC Form SCHEDULE 13D filed by Seer Inc.SCHEDULE 13D - Seer, Inc. (0001726445) (Subject)
- INSIDERPRESIDENT & CFO Horn David R. sold $15,447 worth of shares (7,743 units at $1.99), decreasing direct ownership by 2% to 501,262 units (SEC Form 4)4 - Seer, Inc. (0001726445) (Issuer)
- INSIDERCEO AND CHAIR Farokhzad Omid sold $48,646 worth of shares (24,385 units at $1.99), decreasing direct ownership by 0.72% to 3,349,064 units (SEC Form 4)4 - Seer, Inc. (0001726445) (Issuer)
- PRLeading Scientists Demonstrate How Seer's Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026REDWOOD CITY, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation in the 2026 U.S. Human Proteome Organization (US HUPO) Annual Conference, taking place February 21-25 in St. Louis, Missouri. At the meeting, researchers will demonstrate how Seer's Proteograph® Product Suite is enabling them to tackle complex questions in major disease areas, while supporting the scaling requirements needed for clinical and population health applications. US HUPO has emerged as an important venue for evaluating how new proteomic technologies perform when applied to real-world research